Twice-weekly pyrimethamine-sulfadoxine effectively prevents pneumocystis carinii pneumonia relapse and toxoplasmic encephalitis in patients with AIDS

Journal of Infection

Volumn 42, Issue 1, 2001, Pages 8-15

  Schurmann D ^a,b   Bergmann, F ^a,b   Albrecht, H ^a,b   Padberg, J ^a,b   Grunewald T ^a,b   Behnsch, M ^a,b   Grobusch, M ^a,b   Vallee M ^a,b   Wunsche T ^a,b   Ruf, B ^a,b   Suttorp, N ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; FANSIDAR; FOLINIC ACID; IMMUNOGLOBULIN G;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBODY DETECTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; ENCEPHALITIS; FEMALE; FEVER; HUMAN; HYPERSENSITIVITY REACTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PNEUMOCYSTIS PNEUMONIA; PROSPECTIVE STUDY; PRURITUS; RASH; RELAPSE; SKIN ALLERGY; STEVENS JOHNSON SYNDROME; TOXOPLASMOSIS;

EID: 0034930068     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2000.0772     Document Type: Article

References (49)

1. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
2. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome
3. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii Pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both
4. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens
5. Meta-analysis of prophylactic treatment against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients
6. Prophylaxis of Pneumocystis carinii infection in AIDS with pyrimethamine-sulfadoxine
7. Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients
8. Pyrimethamine/sulfadoxine for prevention of Pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus
9. Administration of pyrimethamine/sulfadoxine for prevention of Pneumocystis carinii pneumonia in patients with AIDS
10. A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS
11. Pyrimethamine and sulfadoxine as a preventive treatment for Pneumocystis carinii pneumonia and Toxoplasma encephalitis
12. Toxoplasmosis
13. Toxoplasmic encephalitis in AIDS
14. Clindamycin/primaquine versus trimethoprim/sulfamethoxazole in primary treatment of Pneumocystis carinii pneumonia
15. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine
16. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
17. Prophylaxis for Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus
18. Prophylaxis for toxoplasmosis in AIDS
19. Toxoplasma gondii infection in advanced HIV infection
20. Risk factors for severe disease due to Toxoplasma gondii in HIV-positive patients
21. Extracerebral toxoplasmosis in AIDS. Histological and immunohistological findings based on 80 autopsy cases
22. USPHP/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: A summary
23. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial
24. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex
25. Delta: A randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
26. Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients
27. Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease
28. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS
29. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients
30. Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex
31. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: An open randomized prospective trial to assess efficacy and haematological toxicity
32. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis
33. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS
34. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with HIV
35. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis
36. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection
37. Fansidar prophylaxis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome
38. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death
39. Adverse reactions to pyrimethamine-sulfadoxine in context of AIDS
40. The safety of pyrimethamine and sulfadoxine for the prevention of Pneumocystis carinii pneumonia
41. Efficacy of sulfadoxine-pyrimethamine for the prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection
42. Fansidar-associated fatal reaction in an HIV-infected man
43. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar®) for malaria prophylaxis
44. How frequent are notified severe cutaneous adverse reactions to Fansidar®
45. Adverse reactions associated with pyrimethamine-sulfadoxine prophylaxis for Pneumocystis carinii infections in AIDS
46. Fatal toxic epidermal necrolysis during prophylaxis with pyrimethamine and sulfadoxine in a human immunodeficiency virus-infected person
47. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: Allergic or toxic?
48. Adverse reactions to pyrimethamine-sulfadoxine
49. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: Experience with 41 cases and a hypothesis regarding pathogenesis